More on LTRN
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $3.88 |
|
|||
| Open | $3.98 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $4.10 | ||||
| Day Low | $3.80 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 117,196 | ||||
- Lantern Pharma (LTRN) files for 2.24M share offering by selling stockholders
- Form S-1 Lantern Pharma Inc.
- New to The Street Broadcasts Tonight on Bloomberg Television Across the United States, Latin America, and MENA at 6:30 PM ET
- Lantern Pharma reports extended survival in lung cancer trial
- Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer
- Form 8-K Lantern Pharma Inc. For: Jun 01
- New to The Street Broadcasts Nationwide on Bloomberg Television Featuring "Opportunities To Consider(TM)" Across Artificial Intelligence, Healthcare Innovation, Fintech, Digital Assets, and Commoditie
- New to The Street Broadcasts Episode 753 Today at 6:30 PM EST Across Bloomberg Television U.S., MENA, and Latin America Featuring Leaders in VR Defense Training, AI Streaming, Healthcare Innovation, a
- Form D Lantern Pharma Inc.
- Lantern Pharma receives FDA clearance for HARMONIC trial amendments
Entities mentioned with LTRN
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- IPO | View Related Stories »
- Definitive Agreement | View Related Stories »
- Show More...
